ADA and psoriasis: The largest early treatment differences (guselkumab minus ADA percentage improvement at week 4) were observed for pathways involved in cell cycle control, hyperplasia, and altered differentiation that characterize psoriasis (ie, mitotic roles of polo-like kinase [49%], chromosomal replication cell cycle [48%], GADD45 signaling [36%], G2/M DNA damage cell cycle [41%], granzyme B signaling [26%], phospholipases [36%], estrogen-mediated S-phase entry [37%], cyclins and cell cycle regulation [30%], p38 MAPK signaling [28%], and G1/S checkpoint cell cycle [25%]) (Figure 4a and Table 3).